Fairmount Funds Management LLC
Director, 10% Owner
- 2024
- Sep 10, 2026
- 26
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Fairmount Funds Management LLC files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Michael Thomas Henderson - $26.88M in APGE purchases and sales in the last 12 months
- Carl Dambkowski - $8.50M in APGE purchases and sales in the last 12 months
- Jane Henderson - $1.36M in APGE purchases and sales in the last 12 months
- Joshua T. Brumm - $921K in CBIO purchases and sales in the last 12 months
- Jonathan McNeill - $447K in CBIO purchases and sales in the last 12 months
- Jan Pinkas - $35K in CBIO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
What is Fairmount Funds Management LLC?
Fairmount Funds Management LLC is an investment firm, tracked as Director, 10% Owner of Cyclerion Therapeutics, Inc. (CYCN). InsiderAlpha holds 26 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Fairmount Funds Management LLC submitted recently?
4 primary Form 4 filings in the last 90 days, covering 3 companies.
Has Fairmount Funds Management LLC been buying or selling stock?
Recorded transactions: 7 open-market purchases ($84.01M) and 5 open-market sales ($1.20B) across all tracked filings.
